Jill Ohar to Treatment Outcome
This is a "connection" page, showing publications Jill Ohar has written about Treatment Outcome.
Connection Strength
0.545
-
Ohar JA, Sharma S, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sanjar S. Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies. COPD. 2019 04; 16(2):133-139.
Score: 0.102
-
Ohar JA, Bowling A, Goodin T, Price B, Ozol-Godfrey A, Sharma S, Sanjar S. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies. Int J Chron Obstruct Pulmon Dis. 2019; 14:461-470.
Score: 0.099
-
Ohar J, Tosiello R, Goodin T, Sanjar S. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. Int J Chron Obstruct Pulmon Dis. 2019; 14:27-37.
Score: 0.098
-
Loh CH, Donohue JF, Ohar JA. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015 Mar; 14(3):463-72.
Score: 0.075
-
Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? Ther Adv Respir Dis. 2013 Apr; 7(2):81-6.
Score: 0.064
-
Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs. 2012 Feb 12; 72(3):301-8.
Score: 0.061
-
Donohue JF, Ohar JA. Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004; 1(3):152-60.
Score: 0.035
-
Cazzola M, Hanania NA, Jones PW, Mahler DA, Make B, Ohar J, Rennard S. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
Score: 0.012